Wound Care Biologics Market by Product (Biological Skin Substitutes (Biosynthetic Products), Topical Agents), Wound Type (Diabetic Foot Ulcer, Pressure Ulcers, Surgical & Traumatic Wound), End User (Hospitals, Burn Centers) - Global Forecast to 2023
[123 Pages Report] The wound care biologics market is expected to reach USD 2.26 Billion by 2023 from USD 1.29 Billion in 2017 at a CAGR of 9.8%. The base year for this study is 2017 and the forecast period is 20182023.
The objectives of this study are as follows:
- To define, describe, and forecast the market by product, wound type, end user, and region
- To forecast the revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
- To identify micromarkets and the drivers, opportunities, and trends affecting the growth of the industry
- To strategically analyze market segments and subsegments with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile key players and comprehensively analyze their market shares and core competencies in terms of market developments and growth strategies
- To track and analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the market
Research Methodology
Top-down and bottom-up approaches were used to estimate and validate the size of wound care biologics industry and the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentationby product, wound type, end user, and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
Various secondary sources such as the International Diabetes Federation (IDF), National Institutes of Health (NIH), Wound Healing Society, European Wound Management Association (EWMA), American Professional Wound Care Association (APWCA), World Health Organization (WHO), American Burn Association, Asian Wound Care Association, Centers for Disease Control and Prevention (CDC), and PubMed have been used to identify and collect information useful for this extensive commercial study of the market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess the prospects of the market. The breakdown of profiles of primaries is shown in the figure below:
To know about the assumptions considered for the study, download the pdf brochure
The major players in wound care biologics market are Smith & Nephew (UK), M๖lnlycke Health Care AB (Sweden), Integra LifeSciences Corporation (US), Wright Medical (US), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Organogenesis (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), and Marine Polymer Technologies, Inc. (US).
Target Audience for this Report:
- Manufacturers and vendors of wound care biologics
- Distributors of wound care biologics
- Venture capitalists
- Various research and consulting firms
- Hospitals and clinics
- Home care settings
- Government associations dedicated to wound care
Scope of the Report:
This report categorizes the wound care biologics market into the following segments:
-
Wound Care Biologics Market, By Product
- Biologic Skin Substitutes
- Human Donor Tissue-derived Products
- Acellular animal-derived Products
- Biosynthetic Products
- Topical Agents
- Biologic Skin Substitutes
-
By Wound Type
- Ulcers
- Venous Ulcers
- Diabetic Foot Ulcers
- Pressure Ulcers
- Other Ulcers
- Surgical and Traumatic Wounds
- Burns
- Ulcers
-
By End User
- Hospitals
- ASCs
- Burn Centers and Wound Clinics
-
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- RoE
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Rest of the World
- North America
Customization Options:
- Company Information: Detailed company profiles of five or more market players
- Opportunity Assessment: A detailed report underlining the various growth opportunities presented in the market
The global wound care biologics market is expected to reach USD 2.26 Billion by 2023 from USD 1.42 Billion in 2018, at a CAGR of 9.8%. Market growth is mainly driven by factors such as the increasing incidence of diabetic foot ulcers, increasing geriatric population, and increasing burn injuries globally. On the other hand, the high cost of wound care biologics and the higher rejection rate associated with skin grafts & substitutes will restrain the growth of this market.
The global market is segmented on the basis of product, wound type, end user, and region. By product, the market segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is estimated to account for the largest share of the market in 2018. The rising incidence of hard-to-heal wounds and their growing adoption (due to their high efficacy) are driving the growth of this product segment. The biological skin substitutes segment is further categorized into human donor tissue-derived products, acellular animal-derived products, and biosynthetic products.
On the basis of wound type, the market is segmented into ulcers, surgical & traumatic wounds, and burns. In 2018, the ulcers segment is expected to account for the largest share of the market. Market growth can primarily be attributed to the widespread adoption of wound care biologics for the treatment of ulcers and burn injuries in developed countries and the high incidence rate of diabetic foot ulcers.
On the basis of end user, the market is segmented into hospitals, ASCs, and burn centers & wound clinics. In 2017, the hospitals segment accounted for the largest share of the market. Hospitals are the largest end users of wound care biologics, as most of the wound care treatment using biologics are conducted in hospital settings.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America is expected to command the largest share of the market. The large share of this segment can primarily be attributed to the high presence of key players in this region, the availability of a variety of wound biologics products, and the high prevalence of diabetic foot ulcers this region.
However, the Asia Pacific market is estimated to register the highest growth during the forecast period primarily due to the presence of a large patient population, increasing penetration of key market players, and the large number of research and development activities for wound care biologic products.
Some of the major players in the wound care biologics market are Smith & Nephew (UK), M๖lnlycke Health Care AB (Sweden), Integra LifeSciences Corporation (US), Wright Medical (US), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Organogenesis (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), Lavior Inc. (US), and Marine Polymer Technologies, Inc. (US). These companies have products for all end users in this market, a strong geographical presence, and a focus on continuous product innovation.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 12)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology (Page No. - 15)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 23)
4 Premium Insights (Page No. - 26)
4.1 Global Market Overview
4.2 Geographic Analysis: Market, By Product (2018)
4.3 Geographic Snapshot of the Market
4.4 Market, By Wound Type
5 Overview (Page No. - 30)
5.1 Introduction
5.2 Reimbursement Scenario for Skin Substitutes in the US
5.2.1 General Criteria Covered
5.2.2 Apligraf, Theraskin, and Epifix
5.2.3 Dermagraft
5.2.4 Integra
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Incidences of Burn Injuries
5.3.1.2 Rapid Growth in the Geriatric Population
5.3.1.3 Growing Incidence of Ulcers and Target Conditions
5.3.1.4 Innovation in Wound Care Biologics
5.3.1.5 Awareness Programs for Wound Care Treatment and Management
5.3.2 Market Restraints
5.3.2.1 High Cost of Wound Treatment and Wound Care Biologics
5.3.2.2 Risk of Skin Substitute Failure
5.3.3 Market Opportunities
5.3.3.1 Increasing Research on Advanced Wound Treatments
5.3.3.2 3d Skin Printing
6 Wound Care Biologics Market, By Product (Page No. - 39)
6.1 Introduction
6.2 Biological Skin Substitutes
6.2.1 Human Donor Tissue-Derived Products
6.2.2 Acellular Animal-Derived Products
6.2.3 Biosynthetic Products
6.3 Topical Agents
7 By Wound Type (Page No. - 46)
7.1 Introduction
7.2 Ulcers
7.2.1 Diabetic Foot Ulcers
7.2.2 Venous Ulcers
7.2.3 Pressure Ulcers
7.2.4 Other Ulcers
7.3 Surgical & Traumatic Wounds
7.4 Burns
8 By End User (Page No. - 58)
8.1 Introduction
8.2 Hospitals
8.3 Ambulatory Surgical Centers
8.4 Burn Centers and Wound Clinics
9 By Region (Page No. - 63)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 UK
9.3.2 Germany
9.3.3 France
9.3.4 RoE
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 Rest of Asia Pacific
9.5 Rest of the World
10 Competitive Landscape (Page No. - 90)
10.1 Overview
10.2 Market Share Ranking, 2017
10.3 Top Ranking Companies in the Wound Care Biologics Market
10.4 Market Share Analysis in the Us, 2017
10.5 Competitive Scenario
10.5.1 Product Launches and Approvals
10.5.2 Agreements
10.5.3 Acquisitions
10.5.4 Expansions
10.5.5 Other Developments
11 Company Profiles (Page No. - 95)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 Smith & Nephew
11.2 M๖lnlycke Health Care AB (Investor AB)
11.3 Integra Lifesciences
11.4 Wright Medical
11.5 Mimedx Group
11.6 Vericel
11.7 Anika Therapeutics
11.8 Osiris Therapeutics
11.9 Organogenesis
11.10 Kerecis
11.11 Solsys Medical
11.12 Acell
11.13 Marine Polymer Technologies
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
12 Appendix (Page No. - 116)
12.1 Insights From Industry Experts
12.2 Discussion Guide
12.3 Knowledge Store: Marketsandmarkets Subscription Portal
12.4 Introducing RT: Real-Time Market Intelligence
12.5 Available Customizations
12.6 Related Reports
12.7 Author Details
List of Tables (87 Tables)
Table 1 Major Skin Substitutes Available in the World Market
Table 2 Increase in Aging Population, By Region, 2015 vs 2050 (Million)
Table 3 Prevalence of Chronic Wounds in the Aging Population
Table 4 Age-Specific Prevalence of Diabetic Foot Ulcers, By Gender
Table 5 Prevalence of Diabetic Foot Ulcers, 2016
Table 6 List of Commercially Available Skin Substitutes, Their Indications, and Supporting Evidence for Use in Chronic Wounds
Table 7 Recently Launched Technologically Wound Care Biologics Products
Table 8 Awareness Initiatives Related to Wound Care Biologics
Table 9 Average Cost of Diabetic Foot Ulcer Management (Wagner Classification) in the Us
Table 10 Comparison of Outcomes (Stsg vs Ftsg Patients)
Table 11 By Product, 20162023 (USD Million)
Table 12 Biological Skin Substitutes Commercialized for Wound Treatment
Table 13 Wound Care Biologics Market for Skin Substitutes, By Region, 20162023 (USD Million)
Table 14 Market for Biological Skin Substitutes, By Type, 20162023 (USD Million)
Table 15 Commercialized Human Donor Tissue-Derived Products
Table 16 Human Donor Tissue-Derived Products Market, By Region, 20162023 (USD Million)
Table 17 Commercialized Acellular Animal-Derived Products
Table 18 Acellular Animal-Derived Products Market, By Region, 20162023 (USD Million)
Table 19 Wound Care Biologics Market for Biosynthetic Products, By Region, 20162023 (USD Million)
Table 20 Market for Topical Agents, By Region, 20162023 (USD Million)
Table 21 Common Components of Wound Care Biologics
Table 22 By Wound Type, 20162023 (USD Million)
Table 23 Medically Necessary Bioengineered Skin Substitutes
Table 24 Wound Care Biologics Market for Ulcers, By Type, 20162023 (USD Million)
Table 25 Market for Ulcers, By Region, 20162023 (USD Million)
Table 26 Prevalence Rate of Diabetic Foot Ulcers in Major Countries (2016)
Table 27 Average Treatment Cost for Diabetic Foot Ulcers in the US (2015)
Table 28 Wound Care Biologics Market for Diabetic Foot Ulcers, By Region, 20162023 (USD Million)
Table 29 Market for Venous Ulcers, By Region, 20162023 (USD Million)
Table 30 Wound Care Biologics Market for Pressure Ulcers, By Region, 20162023 (USD Million)
Table 31 Commercially Available Wound Care Biologic Products for Other Ulcers
Table 32 Wound Care Biologics Market for Other Ulcers, By Region, 20162023 (USD Million)
Table 33 Market for Surgical & Traumatic Wounds, By Region, 20162023 (USD Million)
Table 34 Average Hospital Admissions for the Treatment of Burn Injuries (2015)
Table 35 Skin Replacements Commercialized for the Treatment of Burns
Table 36 Wound Care Biologics Market for Burns, By Region, 20162023 (USD Million)
Table 37 Market, By End User, 20162023 (USD Million)
Table 38 Wound Care Biologics Market for Hospitals, By Region, 20162023 (USD Million)
Table 39 Price Assessment of Wound Care Biologics in Ambulatory Surgical Centers in the Us
Table 40 Market for Ambulatory Surgical Centers, By Region, 20162023 (USD Million)
Table 41 Market for Burn Centers and Wound Clinics, By Region, 20162023 (USD Million)
Table 42 Market, By Region, 20162023 (USD Million)
Table 43 North America: Market, By Country, 20162023 (USD Million)
Table 44 North America: Market, By Product, 20162023 (USD Million)
Table 45 North America: Market, By Wound Type, 20162023 (USD Million)
Table 46 North America: Market, By End User, 20162023 (USD Million)
Table 47 Major Skin Substitutes Launched in the Us
Table 48 US: Market, By Product, 20162023 (USD Million)
Table 49 US: Market, By Wound Type, 20162023 (USD Million)
Table 50 US: Market, By End User, 20162023 (USD Million)
Table 51 Canada: Market, By Product, 20162023 (USD Million)
Table 52 Canada: Market, By Wound Type, 20162023 (USD Million)
Table 53 Canada: Market, By End User, 20162023 (USD Million)
Table 54 Prevalence of Diabetes in Europe, 20152040
Table 55 Europe: Market, By Country, 20162023 (USD Million)
Table 56 Europe: Market, By Product, 20162023 (USD Million)
Table 57 Europe: Market, By Wound Type, 20162023 (USD Million)
Table 58 Europe: Market, By End User, 20162023 (USD Million)
Table 59 UK: Market, By Product, 20162023 (USD Million)
Table 60 UK: Market, By Wound Type, 20162023 (USD Million)
Table 61 UK: Market, By End User, 20162023 (USD Million)
Table 62 Germany: Market, By Product, 20162023 (USD Million)
Table 63 Germany: Market, By Wound Type, 20162023 (USD Million)
Table 64 Germany: Market, By End User, 20162023 (USD Million)
Table 65 France: Market, By Product, 20162023 (USD Million)
Table 66 France: Market, By Wound Type, 20162023 (USD Million)
Table 67 France: Market, By End User, 20162023 (USD Million)
Table 68 RoE: Market, By Product, 20162023 (USD Million)
Table 69 RoE: Market, By Wound Type, 20162023 (USD Million)
Table 70 RoE: Market, By End User, 20162023 (USD Million)
Table 71 APAC: Market, By Country, 20162023 (USD Million)
Table 72 APAC: Market, By Product, 20162023 (USD Million)
Table 73 APAC: Market, By Wound Type, 20162023 (USD Million)
Table 74 APAC: Market, By End User, 20162023 (USD Million)
Table 75 China: Market, By Product, 20162023 (USD Million)
Table 76 China: Market, By Wound Type, 20162023 (USD Million)
Table 77 China: Market, By End User, 20162023 (USD Million)
Table 78 Japan: Market, By Product, 20162023 (USD Million)
Table 79 Japan: Market, By Wound Type, 20162023 (USD Million)
Table 80 Japan: Market, By End User, 20162023 (USD Million)
Table 81 RoAPAC: Market, By Product, 20162023 (USD Million)
Table 82 RoAPAC: Market, By Wound Type, 20162023 (USD Million)
Table 83 RoAPAC: Market, By End User, 20162023 (USD Million)
Table 84 RoW: Diabetic Population, By Region
Table 85 RoW: Market, By Product, 20162023 (USD Million)
Table 86 RoW: Market, By Wound Type, 20162023 (USD Million)
Table 87 RoW: Market, By End User, 20162023 (USD Million)
List of Figures (32 Figures)
Figure 1 Global Wound Care Biologics Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market: Bottom-Up Approach
Figure 5 Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Market, By Product, 2018 vs 2023 (USD Billion)
Figure 8 Market, By Wound Type, 2018 vs 2023 (USD Billion)
Figure 9 Market, By End User, 2018 vs 2023 (USD Billion)
Figure 10 Market, By Region, 2018 vs 2023 (USD Billion)
Figure 11 High Prevalence and Increasing Incidence Rate of Diabetic Foot Ulcers to Drive Market Growth
Figure 12 Biological Skin Substitutes to Dominate the North American Market in 2018
Figure 13 Asia Pacific to Register the Highest CAGR During the Forecast Period
Figure 14 Biological Skin Substitutes to Dominate the Market During 2018 to 2023
Figure 15 Market: Drivers, Restraints, and Opportunities
Figure 16 Incidence of Diabetes, By Region (2015 vs 2040)
Figure 17 Biological Skin Substitute Segment to Witness the Highest Growth During the Forecast Period
Figure 18 Ulcers Segment to Witness the Highest Growth During the Forecast Period
Figure 19 Hospitals are Estimated to Be the Largest End Users of Wound Care Biologics in 2018
Figure 20 North America to Dominate the Market in 2018
Figure 21 North America: Market Snapshot
Figure 22 Wound Prevalence in the US (2013)
Figure 23 Asia Pacific : Market Snapshot
Figure 24 Product Launches, the Most Adopted Growth Strategy From 2015 to 2018
Figure 25 Smith & Nephew: Company Snapshot
Figure 26 M๖lnlycke Health Care AB (Investor AB): Company Snapshot
Figure 27 Integra Lifesciences: Company Snapshot
Figure 28 Wright Medical: Company Snapshot
Figure 29 Mimedx Group: Company Snapshot
Figure 30 Vericel: Company Snapshot
Figure 31 Anika Therapeutics: Company Snapshot
Figure 32 Osiris Therapeutics: Company Snapshot
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Wound Care Biologics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Wound Care Biologics Market